Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2025-03-07 00:00:00 ET · period of report 2025-03-05 · accession 0001415889-25-007431 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-07 | 2025-03-05 | ARTV | Aslan Fred | Pres, CEO, Dir | A - Grant | $0.00 | +200.0K | 416.7K | +92% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-05 | A | A | 200,000 | $0.00 | 416,665 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. (F2) Reflects reduction in the number of shares subject to the RSU granted on July 22, 2024 from 228,905 shares to 216,665 shares. The equity award was originally calculated based on the maximum offering size of the Company's initial public offering (IPO) and such award was subsequently adjusted following the partial exercise of the underwriters option to purchase additional shares in connection with the IPO. |